Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL

Sasanka Handunnetti • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Sasanka Handunnetti, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of an undetectable peripheral blood MRD status as a therapeutic goal in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated with venetoclax in a retrospective analysis. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Sasanka Handunnetti

3:06
Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM update
Sasanka Handunnetti • 7 Dec 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals